The overarching goal of the Clinical Core is to provide well-characterized patients and controls for dementia research. This Core will recruit, evaluate, and maintain several research cohorts, including Alzheimer's disease (100), frontotemporal lobar degeneration (75), frontotemporal lobar degeneration with motor neuron disease (10), corticobasal degeneration and progressive supranuclear palsy (30), Creutzfeldt-Jakob disease (20), mild cognitive impairment (100), and healthy elderly controls (100). In addition, as part of a larger minority outreach effort, we will recruit and maintain a cohort of 100 Chinese-Americans (50 cognitively impaired, 50 controls). Each subject will receive state-of-the-art clinical assessments. These will include quantitative neurological examinations and clinical histories, functional assessments, evaluation of memory, language, executive function and other cognitive skills, social/personality function, neurobehavior, and functional abilities. Blood will be drawn in order to bank serum, DNA and cell lines. Subjects will be referred to the imaging Core. Subjects will be carefuUy followed longitudinally, with most components of the evaluation repeated annually. In conjunction with the Data Management and Statistics Core, subject data will be made available to researcher for hypothesis testing, subjects will be selected for enrollment into the ADRC RO1s, pilot studies, and other projects, and referrals to the Neuropathology Core will be facilitated.
| Orr, Anna G; Lo, Iris; Schumacher, Heike et al. (2018) Istradefylline reduces memory deficits in aging mice with amyloid pathology. Neurobiol Dis 110:29-36 |
| Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064 |
| Watson, Christa L; Possin, Katherine; Allen, I Elaine et al. (2018) Visuospatial Functioning in the Primary Progressive Aphasias. J Int Neuropsychol Soc 24:259-268 |
| Casaletto, K B; Elahi, F M; Fitch, R et al. (2018) A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence? Cytokine 111:481-489 |
| Tan, Chin Hong; Fan, Chun Chieh; Mormino, Elizabeth C et al. (2018) Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition. Acta Neuropathol 135:85-93 |
| Mok, Sue-Ann; Condello, Carlo; Freilich, Rebecca et al. (2018) Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat Struct Mol Biol 25:384-393 |
| Sturm, Virginia E; Brown, Jesse A; Hua, Alice Y et al. (2018) Network Architecture Underlying Basal Autonomic Outflow: Evidence from Frontotemporal Dementia. J Neurosci 38:8943-8955 |
| Erkkinen, Michael G; Zúñiga, Raquel Gutiérrez; Pardo, Cristóbal Carnero et al. (2018) Artistic Renaissance in Frontotemporal Dementia. JAMA 319:1304-1306 |
| Bonham, Luke W; Geier, Ethan G; Steele, Natasha Z R et al. (2018) Insulin-Like Growth Factor Binding Protein 2 Is Associated With Biomarkers of Alzheimer's Disease Pathology and Shows Differential Expression in Transgenic Mice. Front Neurosci 12:476 |
| Schneider, Raphael; McKeever, Paul; Kim, TaeHyung et al. (2018) Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89:851-858 |
Showing the most recent 10 out of 590 publications
